Finance

Something Ventured By Kate Sheridan

Oncorus and three other startups got venture funding a year ago. Did it help them do what they said it would?

Health Tech By Andy Rosen — Boston Globe

Biofourmis raises $100 million for remote patient monitoring tools

Health Tech By Rebecca Robbins

What we learned about the business of telemedicine from Amwell and GoodRx’s IPO filings

Health Tech By Rebecca Robbins

STAT+ Conversations: 23andMe CEO says spit kit sales are picking up during the Covid-19 pandemic

Health Tech By Rebecca Robbins

Johnson & Johnson invests in Thirty Madison, signaling the resilience of pharma’s interest in health tech

The Readout LOUD By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Listen: A health tech mega-deal, a Twitter vaccine debate, and media criticism from Operation Warp Speed

Health Tech By Rebecca Robbins, Casey Ross, and Erin Brodwin

10 burning questions about Teladoc’s $18.5 billion deal to buy Livongo

Health Tech By Rebecca Robbins

Earnings season highlights how health tech companies fared in the first full quarter of the pandemic

Health By Rebecca Robbins

Medical nonprofits are hard-hit as the pandemic upends crucial fundraising

The Readout LOUD By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Listen: Inside the NBA bubble, a DIY coronavirus vaccine, and the real VC numbers

Pharma By Kate Sheridan

Venture capitalists are still showering biotechs with cash, even as the coronavirus upends markets

Health Tech By Rebecca Robbins

MacKenzie Scott, with a massive Amazon fortune, emerges as a public health philanthropist

Biotech By STAT staff

STAT+ Conversations: Which biotech venture capitalist funds are performing best?

Biotech By Kate Sheridan

Among biotech venture capital firms, Flagship Pioneering got the best single-fund returns

First Opinion By Eric Letsinger and Alison Rein

Invest in community-based organizations to put health dollars where they are really needed

Health Tech By Erin Brodwin

Seeking EU approval on acquisition, Google pledges not to use Fitbit health data to target ads

Health Tech By Erin Brodwin

As European Commission decision looms, Google faces continued scrutiny over Fitbit deal

Health Tech By Juliet Isselbacher

Proving predictions wrong, health tech funding keeps climbing

Health Tech By Rebecca Robbins

Smart pill maker Proteus files for bankruptcy, reveals it has held acquisition talks with Otsuka

First Opinion By Vivian S. Lee

Fee for service is a terrible way to pay for health care. Try a subscription model instead

Biotech By Kate Sheridan

‘An extremely volatile time’: New report underscores the recent roller coaster of the biotech market

Biotech By Jonathan Saltzman — Boston Globe

Medical device startup raises almost $44M to advance a less-invasive treatment for fluid in the brain

Pharmalot By Ed Silverman

Why would AstraZeneca want to buy Gilead? Some analysts say it’s not entirely clear

First Opinion By Eric M. Stone

Covid-19 is changing the game for health care companies and investors

Biotech By Kate Sheridan

Most Read

How Teladoc won: The inside story of how well-timed bets propelled it ahead of the competition

Otsuka approved to buy bankrupt smart-pill maker Proteus’ assets, overcoming opposition from Novartis

Teladoc Health reaches agreement to buy Livongo in a $18.5 billion deal

Blackstone agrees to buy Ancestry in $4.7 billion deal

Teladoc rival MDLive is preparing to go public next year

The novel coronavirus is a serious threat. We need to prepare, not overreact

Lavishly funded Moderna hits safety problems in bold bid to revolutionize medicine

4 questions for neurology startups as venture investors pour millions into the field

All Coverage

Oncorus and three other startups got venture funding a year ago. Did it help them do what they said it would?

Biofourmis raises $100 million for remote patient monitoring tools

What we learned about the business of telemedicine from Amwell and GoodRx’s IPO filings

STAT+ Conversations: 23andMe CEO says spit kit sales are picking up during the Covid-19 pandemic

Johnson & Johnson invests in Thirty Madison, signaling the resilience of pharma’s interest in health tech

Listen: A health tech mega-deal, a Twitter vaccine debate, and media criticism from Operation Warp Speed

10 burning questions about Teladoc’s $18.5 billion deal to buy Livongo

Earnings season highlights how health tech companies fared in the first full quarter of the pandemic

Medical nonprofits are hard-hit as the pandemic upends crucial fundraising

Listen: Inside the NBA bubble, a DIY coronavirus vaccine, and the real VC numbers

Venture capitalists are still showering biotechs with cash, even as the coronavirus upends markets

MacKenzie Scott, with a massive Amazon fortune, emerges as a public health philanthropist

STAT+ Conversations: Which biotech venture capitalist funds are performing best?

Among biotech venture capital firms, Flagship Pioneering got the best single-fund returns

Invest in community-based organizations to put health dollars where they are really needed

Seeking EU approval on acquisition, Google pledges not to use Fitbit health data to target ads

As European Commission decision looms, Google faces continued scrutiny over Fitbit deal

Proving predictions wrong, health tech funding keeps climbing

Smart pill maker Proteus files for bankruptcy, reveals it has held acquisition talks with Otsuka

Fee for service is a terrible way to pay for health care. Try a subscription model instead

‘An extremely volatile time’: New report underscores the recent roller coaster of the biotech market

Medical device startup raises almost $44M to advance a less-invasive treatment for fluid in the brain

Why would AstraZeneca want to buy Gilead? Some analysts say it’s not entirely clear

Covid-19 is changing the game for health care companies and investors

In a first for RNA-modifying drugs, AstraZeneca partners with startup Accent Therapeutics

Most Read

All Coverage